Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Heart failure with preserved ejection fraction: are angiotensin receptor-neprilysin inhibitors the answer?

Heart failure with preserved ejection fraction: are angiotensin receptor-neprilysin inhibitors the answer? Heart Failure with Preserved Ejection Fraction: Are Angiotensin Receptor-Neprilysin Inhibitors the Answer? – Clinical Correlations Search Heart Failure with Preserved Ejection Fraction: Are Angiotensin Receptor-Neprilysin Inhibitors the Answer? January 15, 2020 6 min read By Jad Malas Peer Reviewed According to a 2016 American Heart Association (AHA) report, an estimated 5.7 million (...) Americans over the age of twenty have heart failure. . 1 The AHA and American College of Cardiology Foundation (ACCF) divide heart failure into two categories based upon left ventricular ejection fraction (LVEF): an LVEF < 40% is considered heart failure with reduced ejection fraction (HFrEF), while . 2 HFpEF patients make up approximately half of the total heart failure population, and with an aging population this proportion is expected to increase, as over 90% of patients . 3 Despite the growing

2020 Clinical Correlations

2. L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. (PubMed)

L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Coronary artery bypass grafting reduces plasma L-carnitine and may impair the production of myocardial energy. L-carnitine supplementation may elevate plasma L-carnitine and increase cardiac mechanical efficiency. The objective of this study was to verify the recovery of preoperative plasma LC in patients with heart failure undergoing coronary artery (...) bypass grafting supplemented with a daily oral dose of 50 mg / kg. Volunteers with ischemic heart failure who underwent surgery were randomized into a supplemented group (A-received 50 mg / kg L-carnitine) or placebo group (B) for 60 days. Supplementation was started on the third postoperative day. The spectrophotometric enzymatic method was used to quantify plasma L-carnitine. In the preoperative period, both groups had plasma L-carnitine adequate to the reference range (18.9-71.1 μM). On the second

Full Text available with Trip Pro

2019 Anais da Academia Brasileira de Ciencias Controlled trial quality: uncertain

3. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure

Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure Although torsemide's oral bioavailability and half-life theoretically render it a more efficient diuretic than furosemide, the clinical outcomes of torsemide compared with furosemide remain unclear. We performed a systematic review and meta-analysis, including all published studies that compared torsemide and furosemide use in heart failure patients from January 1996 through August 2019. Nineteen studies (9 (...) randomized control trials [RCTs] and 10 observational studies) with a total of 19,280 patients were included. During a mean follow-up duration of 15 months, torsemide was associated with a numerically lower risk of hospitalization due to heart failure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% confidence interval [CI] [0.51, 1.03], p = 0.07, I2 = 18%; number needed to treat [NNT] = 23) compared with furosemide. Torsemide was associated with statistically significant more improvement in functional status

2019 EvidenceUpdates

4. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) status. EQW's effects on secondary end points based on HHF

2019 EvidenceUpdates

5. Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association

Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Hello Guest! Login to your account Email Password Keep me logged in Search 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. No Access article Share on Jump to No Access article (...) , MD, FAHA, Chair , MD, FAHA, Vice Chair , MD, PhD, FRCPC, FAHA , MD, PhD , MD, MS, FAHA , MD, MS, FAHA , PhD, RN, FAHA , MD , MD, PhD, FAHA Sharon Cresci , Naveen L. Pereira , Ferhaan Ahmad , Mirnela Byku , Lisa de las Fuentes , David E. Lanfear , Carolyn M. Reilly , Anjali T. Owens , Matthew J. Wolf , Originally published 12 Sep 2019 Circulation: Genomic and Precision Medicine. 2019;12:458–485 Abstract One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better

2019 American Heart Association

6. Type 2 Diabetes Mellitus and Heart Failure

Type 2 Diabetes Mellitus and Heart Failure Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March (...) 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update , MD, MS, Co-Chair , MD, FAHA, Co-Chair , MD, FAHA , MD, MHS, FAHA

2019 American Heart Association

7. Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure

Optimizer Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure 1 Public Summary Document Application No. 1387.2 – Optimizer® Smart Implantable Pulse Generator (IPG) – Cardiac Contractility Modulation (CCM) therapy for patients with Chronic Heart Failure Applicant: Impulse Dynamics and Life Systems Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance (...) with its Terms of Reference, visit the MSAC website 1. Purpose of application An application for the resubmission of an implantable pulse generator (IPG) delivering Cardiac Contractility Modulation (CCM) therapy for patients with chronic heart failure was received from Impulse Dynamics Australia Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness

2019 Medical Services Advisory Committee

8. Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study

Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk.All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using

2019 EvidenceUpdates

9. Sacubitril/valsartan for chronic heart failure with reduced ejection fraction

Sacubitril/valsartan for chronic heart failure with reduced ejection fraction '); } else { document.write(' '); } ACE | Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Search > > Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction - Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Published on 2 May 2019 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has (...) not recommended listing sacubitril/valsartan on the Medication Assistance Fund (MAF) for treating chronic heart failure with reduced ejection fraction because of uncertain cost-effectiveness and budget impact at the price proposed by the manufacturer. Quicklinks | | | | | Copyrights © 2019 Ministry of Health, Singapore. Last Updated on 2 May 2019

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

10. Improving Communication in Heart Failure Patient Care

Improving Communication in Heart Failure Patient Care Although implantable cardioverter-defibrillators (ICDs) reduce sudden death, these patients die of heart failure (HF) or other diseases. To prevent shocks at the end of life, clinicians should discuss deactivating the defibrillation function.The purpose of this study was to determine if a clinician-centered teaching intervention and automatic reminders increased ICD deactivation discussions and increased device deactivation.In this 6-center

2019 EvidenceUpdates

11. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. (PubMed)

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal (...) dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality

2019 Lancet

12. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Last updated: May 15, 2019 Project Number: RC1119-000 Product Line: Research Type: Drug (...) Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure and with left ventricular ejection fraction > 35% and 40%? Key Message There were no studies identified with inclusion criteria of patients with stable chronic heart failure and left ventricular ejection fraction greater than 35% and less than or equal to 40% Two studies, however, included patients with LVEF less than 40% and were

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Last updated: March 19, 2019 Project Number: RB1316-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure? Key Message Two randomized controlled trials regarding the clinical effectiveness of ivabradine for patients with stable chronic heart failure were identified. Files Rapid Response Summary of Abstracts Published : March 19, 2019 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

14. Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness (...) , and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 19, 2019 Project Number: RC1163-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and clinical utility of natriuretic peptide testing for the monitoring of heart failure therapy? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness

Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments (...) : Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Last updated: August 27, 2019 Project Number: RB1380-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of point of care ultrasound for the assessment of patients with suspected or known chronic heart failure

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure

Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Translation of the key statement of the final report N16-02 Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz (Version 1.2; Status: 4 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N16-02 Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Extract of final report N16-02 Version 1.2 Telemonitoring using active cardiac implantable devices 4 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Telemonitoring using

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Ivabradine (Lancora) for Heart Failure

Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure | CADTH.ca Find the information you need Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure Last updated: August 8, 2019 Project Number: HO0006-000 Product Line: Technology Review Result type: Report Heart failure is a condition characterized by reduced cardiac output occurring due to complications of cardiovascular disease. It is a leading cause of hospital admissions and has a poor

2019 CADTH - Technology Review

18. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory EXPERT CONSENSUS DECISION PATHWAY 2019 ACC Expert Consensus Decision PathwayonRiskAssessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee Steven M. Hollenberg, MD, FACC, Chair Lynne Warner Stevenson, MD, FACC, Vice Chair Tariq Ahmad, MD, MPH, FACC Vaibhav J. Amin, MD (...) ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure ... - APPENDIX 2 Peer Reviewer Relationships With Industry and Other Entities—2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and ClinicalTrajectoryofPatientsHospitalizedWithHeart Failure .. ... - APPENDIX 3 Abbreviations ... ... - APPENDIX 4 Advance Care Planning .. ... - APPENDIX 5 Alternative Format for the Focused Discharge Handoff

2019 American College of Cardiology

19. The Effect of Renal Denervation on Exercise Tolerance in Patients with Heart Failure

The Effect of Renal Denervation on Exercise Tolerance in Patients with Heart Failure "The Effect of Renal Denervation on Exercise Tolerance in Patients with" by Meredith Dahle < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Heart Failure is a growing clinical syndrome that results in major impacts on patients and the medical system. Previously, therapy has (...) improved symptoms while leaving the patient disabled in the later stages. Renal denervation (RDN) is a procedure that is being researched for its effect on improving the condition of heart failure along with its symptoms and increasing exercise tolerance in patients. Methods: Exhaustive search of available medical literature using MEDLINE via PubMed, CINAHL, Web of Science and Google Scholar using the keywords renal denervation, heart failure and exercise tolerance. The studies that fit the eligibility

2019 Pacific University EBM Capstone Project

20. Cardiac rehabilitation for heart failure can improve quality of life and fitness. (PubMed)

Cardiac rehabilitation for heart failure can improve quality of life and fitness. The studyTaylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess 2019;23:1-98.This project was funded by the NIHR Health Technology Assessment Programme (project number 15/80/30).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000803/cardiac (...) -rehabilitation-for-heart-failure-can-improve-quality-of-life-and-fitness.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ